(2S,5R)-3,3-dimethyl-4,4,7-trioxo-4lambda6-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(6R,7R)-7-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S,5R)-3,3-dimethyl-4,4,7-trioxo-4lambda6-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(6R,7R)-7-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
• 英文别名: (2S,5R)-3,3-dimethyl-4,4,7-trioxo-4λ6-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(6R,7R)-7-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
• 化学式: C33H38N10O13S3
• 分子量: 878.9
• InChiKey: WIKQLQXZUYAZQC-KYNIKAHCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.91
• 重原子数：
  59
• 可旋转键数：
  10
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  371
• 氢给体数：
  5
• 氢受体数：
  18

文献信息

• Pharmaceutical composition for the preparation of infusion solutions of antimicrobial preparations, its production process
  申请人：Limonov, Viktor Lvovich

  公开号：EP2596783A1

  公开（公告）日：2013-05-29

  The present invention relates to pharmacology, medicine, veterinary science and pharmaceutical industry, namely to pharmaceutical compositions for the preparation of infusion solutions of antimicrobial preparations potentiating the therapeutic efficacy of antimicrobial medicaments, during the process of preparing solutions thereof immediately before carrying out intravenous infusions and the process of producing original composite pharmaceutical ingredients. The claimed pharmaceutical compositions for the preparation of injection solutions of all the tested antimicrobial preparations comprising the finely dispersed powder of nanostructured colloidal silica, reliably increase their therapeutic efficacy when treating generalised sepsis in test animals, provoked by Staphylococcus aureus, Escherichia coli, Pseudo-monas aeruginosa and Candida albicans. The claimed pharmaceutical compositions for the preparation of antibacterial and antifungal preparations solutions for intravenous infusions (NaCl:Colloidal silica and Dextrose:Colloidal silica) have a significant clinically sginificant potentiating action on their therapeutic potential when treating inflammatory infectious disease, in comparison with traditional solvents (prototypes of the invention).

  本发明涉及药理学、医学、兽医学和制药业，即在紧接着进行静脉输液之前制备抗菌制剂输液溶液的过程中，以及在生产原始复合药物成分的过程中，制备可增强抗菌药物疗效的药物组合物。 本发明所述的药物组合物用于配制所有经测试的抗菌制剂的注射液，其中包含纳米结构胶体二氧化硅的细微分散粉末，在治疗由金黄色葡萄球菌、大肠杆菌、绿脓杆菌和白色念珠菌引起的试验动物全身败血症时，能可靠地提高其疗效。 与传统溶剂（本发明的原型）相比，用于制备静脉注射用抗菌和抗真菌制剂溶液的药物组合物（氯化钠：胶体二氧化硅和葡萄糖：胶体二氧化硅）在治疗炎症性传染病时具有显著的临床增效作用。
• HIGHLY STABLE NON-VESICULAR NANOPARTICLES AND APPLICATION THEREOF IN TREATING MICROBIAL INFECTION
  申请人：ALAYA (SHANGHAI) BIOSCIENCE CO., LTD

  公开号：EP3351238A1

  公开（公告）日：2018-07-25

  Non-vesicular nanoparticles which have antibacterial activity and are made from a C8-C28 fatty acid or a derivative thereof, a surfactant and an optional lipid.

  具有抗菌活性的非囊状纳米颗粒，由 C8-C28 脂肪酸或其衍生物、表面活性剂和任选脂质制成。
• Methods and compositions for treating conditions associated with an abnormal inflammatory responses
  申请人：First Wave Bio, Inc.

  公开号：US10292951B2

  公开（公告）日：2019-05-21

  This disclosure features chemical entities (e.g., a compound exhibiting activity as a mitochondrial uncoupling agent or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as niclosamide or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as a niclosamide analog, or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof) that are useful, e.g., for treating one or more symptoms of a pathology characterized by an abnormal inflammatory response (e.g., inflammatory bowel diseases) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.

  本公开的化学实体（例如，具有线粒体解偶联剂活性的化合物或其药学上可接受的盐和/或水合物和/或共晶体；例如，化合物，如烟酰胺或其药学上可接受的盐和/或水合物和/或共晶体；例如、化合物，如尼可刹米类似物，或其药学上可接受的盐和/或水合物和/或共晶体），这些化合物可用于治疗受试者（如人类）中以异常炎症反应（如炎症性肠病）为特征的病理学的一种或多种症状。本公开内容还包括组合物以及使用和制造组合物的其他方法。
• Methods and compositions for treating conditions associated with an abnormal inflammatory response
  申请人：First Wave Bio, Inc.

  公开号：US10772854B2

  公开（公告）日：2020-09-15

  This disclosure features chemical entities (e.g., a compound exhibiting activity as a mitochondrial uncoupling agent or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as niclosamide or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as a niclosamide analog, or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof) that are useful, e.g., for treating one or more symptoms of a pathology characterized by an abnormal inflammatory response (e.g., inflammatory bowel diseases) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.

  本公开的化学实体（例如，具有线粒体解偶联剂活性的化合物或其药学上可接受的盐和/或水合物和/或共晶体；例如，化合物，如烟酰胺或其药学上可接受的盐和/或水合物和/或共晶体；例如、化合物，如尼可刹米类似物，或其药学上可接受的盐和/或水合物和/或共晶体），这些化合物可用于治疗受试者（如人类）中以异常炎症反应（如炎症性肠病）为特征的病理学的一种或多种症状。本公开内容还包括组合物以及使用和制造组合物的其他方法。
• Methods of treatment
  申请人：First Wave Bio, Inc.

  公开号：US10980756B1

  公开（公告）日：2021-04-20

  This disclosure features compounds and compositions that are useful in methods of treating coronavirus infections (e.g., useful in methods of treating COVID-19) in a subject in need thereof. The methods include administering to the subject niclosamide compounds (or pharmaceutically acceptable salts and/or co-crystals thereof, e.g., niclosamide). In some embodiments, the niclosamide compounds have one or more properties that include, but are not limited to: a particular purity (e.g., a chemical purity of greater than about 99.0%) or a particular particle size (e.g., a particular particle size distribution and/or a particular particle size range and/or a specific surface area range). In an aspect, the niclosamide compounds described herein (e.g., niclosamide) can form part of compositions, dosage forms (e.g., unit dosage forms), and the like, which are suitable for respiratory administration (e.g., via inhalation and/or intranasally). In another aspect, the niclosamide compounds described herein (e.g., niclosamide) can form part of compositions, dosage forms (e.g., unit dosage forms), and the like, which are suitable for administration to the GI tract (e.g., orally or rectally such as via enema)).

  本公开的化合物和组合物适用于治疗有需要的受试者的冠状病毒感染的方法（例如，适用于治疗COVID-19的方法）。这些方法包括向受试者施用烟酰胺化合物（或其药学上可接受的盐和/或共晶体，例如烟酰胺）。在一些实施方案中，烟酰胺化合物具有一种或多种特性，包括但不限于：特定的纯度（例如化学纯度大于约99.0%）或特定的粒度（例如特定的粒度分布和/或特定的粒度范围和/或比表面积范围）。在一个方面，本文所述的烟酰胺化合物（如烟酰胺）可以构成组合物、剂型（如单位剂型）等的一部分，适合呼吸道给药（如通过吸入和/或鼻内给药）。在另一方面，本文所述的烟酰胺化合物（如烟酰胺）可构成组合物、剂型（如单位剂型）等的一部分，适合于消化道给药（如口服或直肠给药，如通过灌肠））。